test

Colorectal Cancer

10
A Phase II Multi-center, Randomized, Placebo-Controlled Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster
A Phase III, Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Disease/Condition: Colon
Principal Investigator: Sajid Khan
A Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors
Principal Investigator: Melinda Irwin
Novartis Signature - LGX818 for pts with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
Phase 2 study of PF-05212384 plus irinotecan vs. cetuximab plus irinotecan in KRAS & NRAS wt mCLC
Disease/Condition: Anus | Colon
Principal Investigator: Howard Hochster
Phase 3 Study of Adjuvant Regorafenib vs. Placebo for Patients with Stage 4 colorectal cancer
Disease/Condition: Colon | Liver | Rectum
Principal Investigator: Howard Hochster
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Phase Ib/II study of LGX818 and cetuximab or LGX818, BYL719 and cetuximab in BRAF mutant mCRC
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster
Pilot Trial of KD018 with Neo-Adj Concurrent Chemo-RT in PTs with Rectal CA
Disease/Condition: Rectum
Principal Investigator: Susan Higgins
STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regiments (Concurrent and Sequential) vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster